The study was a large, rigorous, multicenter randomized placebo-controlled trial with 33 authors, carried out at 14 Veterans Affairs (VA) medical centers. It enrolled 613 patients age 53 to 96 with a diagnosis of possible or probable AD of mild to moderate severity who were already taking an acetylcholinesterase inhibitor (AChEI). 65% were on Donepezil, 32% on Galantamine, and 3% on Rivastigmine.
The results showed that participants got worse over the period of the study. However, individuals in the vitamin E group had a significantly slower decline than those in the placebo group (3.15 units less on the ADCS-ADL Inventory, annual rate of decline 19% less, and delay in progression of 6.2 months). The group taking both vitamin E and memantine did significantly worse than the group taking vitamin E alone. Adherence was estimated at 65-68%, which isn’t all that bad considering the age of patients and the effects of Alzheimer’s. They concluded that 2,000 IU of vitamin E significantly delayed clinical progression in activities of daily living in patients with mild to moderate AD who were also taking AChEI.
The results of this study bring some hope for Alzheimer’s patients but no one should start taking Vitamin E without the supervision of a physician. The Alzheimer’s Association’s call for caution as the high doses used in the ADCS study can negatively interact with other medications, including those prescribed to keep blood from clotting or to lower cholesterol.
|Healthy Origins – Vitamin E 1000 IU – 240 Softgels|
|Source Naturals – Gamma-E 400 Complex- Vitamin E Complex with Tocotrienols 400 mg. – 120 Softgels|